Friday, 13 November 2026European Markets

AZERION Stock Over 10% Down So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of AZERION (AEX-Index: AZRN.AS) fell by a staggering 10.61% to €2.78 at 11:07 EST on Tuesday, after five successive sessions in a row of gains. AEX-Index is falling 0.08% to €763.51, following the last session's downward trend. This seems, up to now, a somewhat down trend exchanging session today.

AZERION's last close was €3.11, 66.2% under its 52-week high of €9.20.

About AZERION

Azerion Group N.V. operates a digital entertainment and media platform worldwide. Its integrated platform offers technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company was founded in 2014 and is headquartered in Schiphol-Rijk, the Netherlands.

Earnings Per Share

As for profitability, AZERION has a trailing twelve months EPS of €-1.72.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -298.1%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AZERION's stock is considered to be oversold (<=20).

More news about AZERION (AZRN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com